FindTrial
Sign In

A study to compare efficacy of intradermal Tranexamic acid injections versus topical Tranexamic acid gel versus topical triple combination (Hydroquinone 2 %, Tretinion 0.025%, Flucinolone acetonide 0.01%) cream in patients suffering from melasma

The comparative study of the efficacy of intradermal tranexamic acid V/S 3% topical tranexamic acid V/S topical triple combination (hydroquinone 2 %, tretinion 0.025%, flucinolone acetonide 0.01%) in melasma.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/07/009158
Enrollment
180
Registered
2017-07-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L818- Other specified disorders of pigmentation

Interventions

Intervention1: Tranexamic acid: Dose- 0.05 ml (4mg/ml) in each cm sq of melasma,Mode of Administration intradermal, Frequency-once in every 15 days, Duration of treatment-03 months. Control Interventi

Sponsors

MGM Medical COllege and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 All melasma patients 2 Willing to give written inform consent

Exclusion criteria

Exclusion criteria: 1 Patients with hypersensitivity to drugs 2 Pregnant and lactating patient 3 Patients with clotting disorders or patients who are on anticoagulant therapy

Design outcomes

Primary

MeasureTime frame
1 To study the efficacy of intradermal tranexamic acid versus topical tranexamic acid versus topical triple combinationTimepoint: Every Month for 06 months—

Secondary

MeasureTime frame
To study adverse effects of study drugs Timepoint: Every month for 06 months—

Countries

India

Contacts

Public ContactDr Shruti Patil

Mahatma Gandhi Missions Medical College & Hospital

ashish7557@gmail.com9422213292

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026